Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Apr 4;12(1):23.
doi: 10.1186/s13019-017-0587-3.

Heartmate 3 fully magnetically levitated left ventricular assist device for the treatment of advanced heart failure -1 year results from the Ce mark trial

Thomas Krabatsch  1 , Ivan Netuka  2 , Jan D Schmitto  3 , Daniel Zimpfer  4 , Jens Garbade  5 , Vivek Rao  6 , Michiel Morshuis  7 , Friedhelm Beyersdorf  8 , Silvana Marasco  9 , Laura Damme  10 , Yuriy Pya  11
Affiliations
Clinical Trial

Heartmate 3 fully magnetically levitated left ventricular assist device for the treatment of advanced heart failure -1 year results from the Ce mark trial

Thomas Krabatsch et al. J Cardiothorac Surg. .

Abstract

Background: The HeartMate 3 Left Ventricular Assist System (LVAS) (St. Jude Medical Inc., St Paul, MN) with full magnetic levitation allows for wide and consistent blood flow paths and an artificial pulse designed for enhanced hemocompatibility. The HeartMate 3 received market approval in the European Union in 2015 following completion of a multicenter study. After reaching the 6-month study endpoint, patients continue to be followed for 2 years with the 1-year results presented herein.

Methods: A prospective, non-randomized study included adults with advanced heart failure and ejection fraction (EF) ≤ 25%, cardiac index (CI) ≤ 2.2 L/min/m2 while not on inotropes, or inotrope dependent, or on optimal medical management for 45/60 days.

Results: Fifty patients-54% bridge to transplant (BTT) and 46% destination therapy (DT)-were enrolled and implanted with the HeartMate 3. At baseline, 92% of the patients were INTERMACS profiles 2-4, with cardiac index 1.8 + 0.5 L/min/m2 and 58% were supported with inotropes. At 1 year, 74% of the patients remain on support, 18% expired, 6% transplanted, and 2% explanted. The adverse events include 12% gastrointestinal bleeding, 16% driveline infections, 18% strokes, and 2% outflow graft thrombosis. There was no hemolysis, pump thrombosis or pump malfunction through 1 year. The six-minute walk test distance increased from a mean of 273 m to 371 m (P <0.0001). EQ-5D quality-of-life score increased from a mean of 52.7 to 70.8 (P = 0.0006).

Conclusions: The 1-year HeartMate 3 LVAS results show survival and adverse-event profile are similar to other approved devices, with no pump thrombosis or pump failure. Patient's functional status and quality of life significantly improved over time.

Trial registration: Clinicaltrials.gov registration number: NCT02170363 . Registered June 19, 2014.

Keywords: Heart failure; HeartMate 3; LVAS; Magnetic levitation.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Kaplan-Meier survival to 1-year after implantation
Fig. 2
Fig. 2
Freedom from gastrointestinal (GI) bleed
Fig. 3
Fig. 3
Freedom from stroke
Fig. 4
Fig. 4
Six-minute walk test data paired for patients with results at baseline and at the specified interval
Fig. 5
Fig. 5
Change in the percent of patients in each NYHA classification at each interval
Fig. 6
Fig. 6
Visual analog score data paired for patients with results at baseline and at the specified interval
See this image and copyright information in PMC

References

    1. Pagani FD, Miller LW, Russell SD, et al. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol. 2009;54:312–321. doi: 10.1016/j.jacc.2009.03.055. - DOI - PubMed
    1. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241–2251. doi: 10.1056/NEJMoa0909938. - DOI - PubMed
    1. John R, Naka Y, Smedira NG, et al. Continuous flow left ventricular assist device outcomes in commercial use compared with the prior clinical trial. Ann Thorac Surg. 2011;92:1406–1413. doi: 10.1016/j.athoracsur.2011.05.080. - DOI - PubMed
    1. Starling RC, Naka Y, Boyle AJ, et al. Results of the post-U.S. Food and drug administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation a prospective study using the INTERMACS (interagency registry for mechanically assisted circulatory support) J Am Coll Cardiol. 2011;57:1890–1898. doi: 10.1016/j.jacc.2010.10.062. - DOI - PubMed
    1. Slaughter MS, Pagani FD, McGee EC, et al. HeartWare ventricular assist system for bridge to transplant: combined results of the bridge to transplant and continued access protocol trial. J Heart Lung Transplant. 2013;32:675–683. doi: 10.1016/j.healun.2013.04.004. - DOI - PubMed

Publication types

Associated data